09/405,046

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1208dxj
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS 3	Feb 06	Engineering Information Encompass files have new names
NEWS 4	Feb 16	TOXLINE no longer being updated
NEWS 5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS 6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA

NEWS EXPRESS	April 18 CURRENT WINDOWS VERSION IS V6.0, CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP), AND CURRENT DISCOVER FILE IS DATED 04/06
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:18:35 ON 07 MAY 2001

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 13:18:39 ON 07 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 6 MAY 2001 HIGHEST RN 334720-68-2
DICTIONARY FILE UPDATES: 6 MAY 2001 HIGHEST RN 334720-68-2

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
Structure search limits have been increased.  See HELP SLIMIT
for details.

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
Uploading C:\STNEXP4\QUERIES\peptide.str

L1       STRUCTURE UPLOADED

=> que L1

L2    QUE L1

=> d
L2 HAS NO ANSWERS
L1                STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L2                QUE  ABB=ON  PLU=ON  L1


=> s l2
SAMPLE SEARCH INITIATED 13:19:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     104 TO ITERATE

100.0% PROCESSED      104 ITERATIONS                                    0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1469 TO     2691
PROJECTED ANSWERS:               0 TO        0

L3             0 SEA SSS SAM L1

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
Uploading C:\STNEXP4\QUERIES\peptide.str

L4       STRUCTURE UPLOADED

=> que L4

L5    QUE L4

=> d
L5 HAS NO ANSWERS
```

```
L4              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L5              QUE  ABB=ON  PLU=ON  L4


=> s l5
SAMPLE SEARCH INITIATED 13:19:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    104 TO ITERATE

100.0% PROCESSED     104 ITERATIONS                                 28 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1469 TO     2691
PROJECTED ANSWERS:             243 TO      877

L6           28 SEA SSS SAM L4

=> fil .search
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                    0.62        0.77

FILE 'MEDLINE' ENTERED AT 13:20:00 ON 07 MAY 2001

FILE 'CAPLUS' ENTERED AT 13:20:00 ON 07 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:20:00 ON 07 MAY 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 13:20:00 ON 07 MAY 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:20:00 ON 07 MAY 2001
COPYRIGHT (C) 2001 Elsevier Science B.V.  All rights reserved.

=> s l6 and (polypeptide? or peptide?)
L7              8 L6 AND (POLYPEPTIDE? OR PEPTIDE?)

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8              8 DUP REM L7 (0 DUPLICATES REMOVED)

=> d ibib ab 1-
YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y
```

L8 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:421115 CAPLUS
DOCUMENT NUMBER: 133:59101
TITLE: Preparation of vitronectin receptor antagonist pharmaceuticals
INVENTOR(S): Cheesman, Edward H.; Sworin, Michael; Rajopadhyem, Milind
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Co., USA
SOURCE: PCT Int. Appl., 228 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035887	A2	20000622	WO 1999-US30311	19991217
WO 2000035887	A3	20001116		

W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: US 1998-112831 P 19981218
OTHER SOURCE(S): MARPAT 133:59101
AB Compds. (Q)d-Ln-Ch (Q is a residue having a benzodiazepine-, benzodiazepinedione-, or dibenzotrihydroannulene-type moiety , d = 1-10, Ln is a linking group, Ch is a metal-bonding unit) were prepd. for use in the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compds. useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. Thus, (S,S,S)-4-[N-[3-[3,6-diaza-10-[N-(benzimidazol-2-ylmethyl)-N-methylcarbamoyl]-5-(carboxymethyl)-4-oxobicyclo[5.4.0]undeca-1(7),8,10-trien-3-yl]propyl]carbamoyl]-4-[[4-carboxy-2-[2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclodecyl]acetylamino]butanoyl]amino]butanoic acid was prepd. (claimed compd.). Syntheses of radiopharmaceticals, e.g., 99mTc(VnA)(tricine)(phosphine), where VnA represents the vitronectin receptor antagonist, are also described.

L8 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:420994 CAPLUS
DOCUMENT NUMBER: 133:59099
TITLE: Preparation of vitronectin receptor antagonist pharmaceuticals
INVENTOR(S): Harris, Thomas David; Rajodadhye, Milind
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 300 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035492	A2	20000622	WO 1999-US30315	19991217
WO 2000035492	A3	20010118		

W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: US 1998-112732 P 19981218
OTHER SOURCE(S): MARPAT 133:59099
AB Compds. (Q)d-Ln-Ch (Q is a residue having a quinolone-type moiety , d = 1-10, Ln is a linking group, Ch is a metal-bonding unit) were prepd. for use in the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compds. useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. Thus, [3-[1-[3-[3-[3-[N-[3-[2-[N-(L-Asp-L-Asp)-3-aminopropoxy]ethoxy]ethoxy]propyl]carbamoyl]propanoylamino]propyl]-7-[(imidazol-2-ylamino)methyl]-4-oxo(3-hydroquinolyl)carbonylamino]-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]propanoic acid DOTA conjugate was prepd. (claimed compd.). Syntheses of radiopharmaceuticals, e.g., 99mTc(VnA)(tricine)(phosphine), where VnA represents the vitronectin receptor antagonist, are also described.

L8 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:420991 CAPLUS
DOCUMENT NUMBER: 133:59098
TITLE: Preparation of vitronectin receptor antagonist pharmaceuticals
INVENTOR(S): Rajopadhye, Milind; Harris, Thomas David; Cheesman, Edward H.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 362 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035488	A2	20000622	WO 1999-US30312	19991217
WO 2000035488	A3	20001109		

W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: US 1998-112829 P 19981218
OTHER SOURCE(S): MARPAT 133:59098
AB Compds. (Q)d-Ln-Ch (Q is a residue having an indazole-type moiety , d = 1-10, Ln is a linking group, Ch is a metal-bonding unit) were prepd. for use in the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compds. useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. Thus, 2-[[[4-[4-[[[3-[2-[2-[3-[[6-[[1-aza-2-(2-sulfophenyl)vinyl]amino](3-pyridyl)]carbonylamino]propoxy]ethoxy]ethoxy]propyl]amino]sulfonyl]phenyl]phenyl]sulfonyl]amino]-3-[[1-[3-(indazole-2-ylamino)propyl](1H-indazol-5-yl)]carbonylamino]propanoic acid was prepd. (claimed compd.). Syntheses of radiopharmaceticals, e.g., 99mTc(VnA)(tricine)(phosphine), where VnA represents the vitronectin receptor antagonist, are also described.

L8 ANSWER 4 OF 8 USPATFULL
ACCESSION NUMBER: 2000:94681 USPATFULL
TITLE: Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
INVENTOR(S): Wedeking, Paul W., Pennington, NJ, United States
Wager, Ruth E., Rockville, MD, United States
Arunachalam, Thangavel, Plainsboro, NJ, United States
Ramalingam, Kondareddiar, Dayton, NJ, United States
Linder, Karen E., Kingston, NJ, United States
Ranganathan, Ramachandran S., Princeton, NJ, United States
Nunn, Adrian D., Lambertville, NJ, United States
Raju, Natarajan, Kendall Park, NJ, United States
Tweedle, Michael F., Princeton, NJ, United States
PATENT ASSIGNEE(S): Bracco Research USA Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6093382	20000725
APPLICATION INFO.:	US 1998-80157	19980516 (9)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Dees, Jose' G.	
ASSISTANT EXAMINER:	Jones, Dameron	
LEGAL REPRESENTATIVE:	Balogh, Imre	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	3756	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Diagnostic and therapeutic compositions in the form of complexes for enhancing transmembrane transport of a diagnostic or therapeutic agent and methods for their use. The complexes contain the .alpha., .gamma., or bis isomers of folate receptor-binding analogs of folate, a metal chelated by a ligand, and in one embodiment, a chemotherapeutic agent.

L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1997:377856 CAPLUS
DOCUMENT NUMBER: 126:343881
TITLE: Preparation of magnetically labeled **peptide** chemoattractants as targeted contrast agents in the NMR imaging of living tissues
INVENTOR(S): Tweedle, Michael F.; Kumar, Krishan; Eaton, Stephen
PATENT ASSIGNEE(S): Bracco International B.V., Neth.
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9714443	A1	19970424	WO 1996-IB1103	19961018
W: JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 814849	A1	19980107	EP 1996-932764	19961018
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 10511701	T2	19981110	JP 1996-515662	19961018
PRIORITY APPLN. INFO.:			US 1995-5669	19951019
			WO 1996-IB1103	19961018

AB The present invention addresses magnetically labeled chemoattractants, e.g. chemotactic **peptides**, for the detection and investigation of diseased or disordered tissue sites or organs in the body of human and animal patients. The chemotactic **peptides** have the general formula N(X)-Y-Leu-Phe-Z-A-W [(X) = H, protective group such as OHC, Ac, Me3CO2C (Boc), or the like; Y = Nle, Met; Z = bond, amino acid, oligopeptide, e.g. N.epsilon.-Lys, Ile, Asp, Nle-Tyr-N.epsilon.Lys, (Gly)n, n = 1-4; A = linker; W = suitably derivatized paramagnetic macrocyclic chelate or magnetic particle]. The invention also concerns physiol. acceptable administrable compns. of formulations comprising the labeled chemoattractants, methods for prepg. the chemoattractants and the formulations, and methods of using the formulations for detecting, localizing and diagnosing infected or inflammatory sites, or other trauma in the organism. Thus, amidation of chemotactic **peptide** OHC-Met-Leu-Phe-OH with macrocycle I (R = H) (prepn. given) gave 40% of **peptide** macrocycle I (R = OHC-Met-Leu-Phe), which reacted with

L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2001 ACS (Continued)
GdCl3 in water at pH 7 at 60.degree. to give 80% of the corresponding monogadolinium salt.

L8 ANSWER 6 OF 8 USPATFULL
ACCESSION NUMBER: 95:58256 USPATFULL
TITLE: Complexes of functionalized tetraazacyclododecane chelates with bismuth, lead, yttrium, actinium, or lanthanide metal ions
INVENTOR(S): Gansow, Otto A., Washington, DC, United States
Brechbiel, Martin W., Annandale, VA, United States
Magerstadt, Michael A., Hofheim, Germany, Federal Republic of
PATENT ASSIGNEE(S): The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	DATE
PATENT INFORMATION:	US 5428154	19950627
APPLICATION INFO.:	US 1993-140714	19931022 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-815956, filed on 2 Jan 1992, now abandoned which is a continuation of Ser. No. US 1988-198538, filed on 25 May 1988, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Higel, Floyd D.
LEGAL REPRESENTATIVE: Leydig, Voit & Mayer, Ltd.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 448
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is a chelate of formula I: ##STR1## wherein R.sub.1-4 is

--CH.sub.2 COOH;

n is 1 to 5;

X is a member selected from the group consisting of

--NO.sub.2,

--NH.sub.2,

--NCS,

--NHCOCH.sub.2 --Z, with Z being a member selected from the group consisting of Br and I,

--COOH; and

--OCH.sub.2 OOCH;

and M is a metal ion selected from the group of elements consisting of

Bi, Pb, Y, Cd, Hg, Al, Th, Sr, and Lanthanides.

The invention also includes a chelate, wherein M is a copper ion and n

L8 ANSWER 6 OF 8 USPATFULL (Continued)
is an integer from 2 to 5. The invention includes chelate conjugates of formula I and ligand conjugates of formula II: ##STR2## The invention also includes methods to use these compounds for treatment of cellular disorders and for diagnostic tests.

L8 ANSWER 7 OF 8 USPATFULL
ACCESSION NUMBER: 94:99669 USPATFULL
TITLE: Polychelants containing macrocyclic chelant moieties
INVENTOR(S): Sieving, Paul F., 3166 Impala Dr. #5, San Jose, CA, United States 95117
Watson, Alan D., 262A Rincon Ave., Campbell, CA, United States 95008
Quay, Steven C., 428 Oakmead Pkwy., Sunnyvale, CA, United States 94086
Rocklage, Scott M., 255 Cresci Rd., Los Gatos, CA, United States 95030

	NUMBER	DATE
PATENT INFORMATION:	US 5364613	19941115
APPLICATION INFO.:	US 1990-464865	19900116 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1989-335162, filed on 7 Apr 1989, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Michl, Paul R.
ASSISTANT EXAMINER: Yoon, Tae H.
LEGAL REPRESENTATIVE: Lyon & Lyon
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
LINE COUNT: 1352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There are provided polychelants and their metal chelates which are useful in diagnostic imaging and in radiotherapy and which comprise a plurality of macrocyclic chelant moieties, e.g, DOTA residues, conjugated to a polyamine backbone molecule, e.g, polylysine. To produce a site-specific polychelate, one or more of the macrocyclic chelant carrying backbone molecules may be conjugated to a site-directed macromolecule, e.g. a protein.

L8 ANSWER 8 OF 8 USPATFULL
ACCESSION NUMBER: 92:61733 USPATFULL
TITLE: Radiolabeled metal-binding protein for the treatment of arthritis
INVENTOR(S): Garlich, Joseph R., Lake Jackson, TX, United States
McMillan, Kenneth, Richwood, TX, United States
Simon, Jaime, Angleton, TX, United States
PATENT ASSIGNEE(S): The Dow Chemical Company, Midland, MI, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5133956	19920728
APPLICATION INFO.:	US 1991-707719	19910530 (7)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Stoll, Robert L.
ASSISTANT EXAMINER: Sayala, C.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Radioactive high molecular weight metal-binding protein compositions and a method for therapeutic radiation treatment including the treatment of rheumatoid arthritis comprising injection of a radioactive high molecular weight metal-binding protein compositions are disclosed.